Condition
Leukemia, Myelogenous, Acute
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
40.0%-47% vs avg
Key Insights
Highlights
Success Rate
40% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
60.0%
3 terminated out of 5 trials
Success Rate
40.0%
-46.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results40% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Terminated3
Completed2
Trial Success Rate
40.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00619879Completed
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
NCT01999556CompletedPrimary
LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia
NCT01158885Phase 2Terminated
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
NCT01106950Phase 2TerminatedPrimary
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
NCT01085656Phase 1TerminatedPrimary
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
Showing all 5 trials